Replies to post #95876 on Biotech Values

[DewDiligence]

I think they are serious about filing in 2010 provided anemia is not a serious issue in the ongoing PIII trials.

The fact that the phase-3 Boceprevir trial addressing anemia is open-label* strengthens your argument.

*http://www.clinicaltrials.gov/ct2/show/NCT01023035 .